bioRxivImmunology
Low-dose lung radiotherapy for COVID-19 lung disease: a pre-clinical efficacy study in a bleomycin model of pneumonitis.
M. R. Jackson, K. Stevenson, S. K. Chahal, E. Curley, G. Finney, R. Gutierrez-Quintana, E. Onwubiko, A. F. Rupp, K. Strathdee, M. K. MacLeod, C. McSharry, A. J. Chalmers
Abstract
PurposeLow-dose whole lung radiotherapy (LDLR) has been proposed as a treatment for patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection and clinical trials are underway. There is an urgent need for preclinical evidence to justify this approach and inform dose, scheduling and mechanisms of action. Materials and methodsFemale C57BL/6 mice were treated with intranasal bleomycin sulphate (7.5 or 11.25 units/kg, day 0), then exposed to whole lung radiation therapy (0.5, 1.0, 1.5 Gy or sham, day 3). Bodyweight was measured daily and lung tissue harvested for histology and flow cytometry on day 10. Computed tomography (CT) lung imaging was performed pre-radiation (day 3) and pre-endpoint (day 10). ResultsBleomycin caused pneumonitis of variable severity which correlated with weight loss. LDLR at 1.0 Gy was associated with a significant increase in the proportion of mice recovering to 98% of initial bodyweight and a proportion of these mice exhibited less severe histopathological lung changes. Mice experiencing moderate initial weight loss were more likely to respond to LDLR than those experiencing severe initial weight loss. Additionally, LDLR (1.0 Gy) significantly reduced bleomycin-induced increases in interstitial macrophages, CD103+ dendritic cells and neutrophil-DC hybrids. Overall,bleomycin-treated mice exhibited significantly higher percentages of non-aerated lung in left than right lungs and LDLR (1.0 Gy) prevented further reductions in aerated lung volume in right but not left lungs. LDLR at 0.5 and 1.5 Gy did not modulate bodyweight or flow cytometric readouts of bleomycin-induced pneumonitis. ConclusionsOur data support the concept that LDLR can ameliorate acute inflammatory lung injury, identify 1.0 Gy as the most effective dose and provide preliminary evidence that it is more effective in the context of moderate than severe pneumonitis. Mechanistically, LDLR at 1.0 Gy significantly suppressed bleomycin-induced accumulation of pulmonary interstitial macrophages, CD103+ dendritic cells and neutrophil-DC hybrids.
- organism: mouse
- assay: imaging
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Low doses of radiation increase the immunosuppressive profile of lung macrophages during viral infection and pneumonia
L. Meziani, C. Robert, … E. Deutsch·bioRxiv·May 11, 2020
- Mice with Induced Pulmonary Comorbidities Display Severe Lung Inflammation and Mortality following Exposure to SARS-CoV-2
- ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
K. S. Konduri, R. Pattisapu, … N. Duzgunes·bioRxiv·May 5, 2021
- Poldip2 deficiency attenuates disease severity in a mouse model of COVID-19
Ruinan Hu, Alejandra Valdivia, … Marina S. Hernandes·bioRxiv·Jun 17, 2025
- CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in murine model of the SARS-CoV-2-related acute respiratory distress syndrome
A. Chernov, M. Rodionov, … A. Belogurov·bioRxiv·Nov 14, 2023
- ADAM17 inhibition prevents neutrophilia and lung injury in a mouse model of Covid-19
N. L. Lartey, S. Valle-Reyes, … M. Schnoor·bioRxiv·Apr 10, 2021